Nutriband (NTRB) announced that it has signed an addendum to the Commercial Development and Clinical Supply Agreement for its lead product, Aversa Fentanyl, that it has in place with its partner, Kindeva Drug Delivery, a global contract development and manufacturing organization, CDMO, focused on drug-device combination products. Nutriband and Kindeva have revised their agreement to formalize their exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. Nutriband is partnering with Kindeva Drug Delivery to develop Aversa Fentanyl which combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.